Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID

Aisha V. Sauer, Immacolata Brigida, Nicola Carriglio, Raisa Jofra Hernandez, Samantha Scaramuzza, Daniela Clavenna, Francesca Sanvito, Pietro L. Poliani, Nicola Gagliani, Filippo Carlucci, Antonella Tabucchi, Maria Grazia Roncarolo, Elisabetta Traggiai, Anna Villa, Alessandro Aiuti

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Adenosine acts as anti-inflammatory mediator on the immune system and has been described in regulatory T cell (Treg)-mediated suppression. In the absence of adenosine deaminase (ADA), adenosine and other purine metabolites accumulate, leading to severe immunodeficiency with recurrent infections (ADA-SCID). Particularly ADA-deficient patients with lateonset forms and after enzyme replacement therapy (PEG-ADA) are known to manifest immune dysregulation. Herein we provide evidence that alterations in the purine metabolism interfere with Treg function, thereby contributing to autoimmune manifestations in ADA deficiency. Tregs isolated from PEG-ADA-treated patients are reduced in number and show decreased suppressive activity, whereas they are corrected after gene therapy. Untreated murine ADA -/- Tregs show alterations in the plasma membrane CD39/CD73 ectonucleotidase machinery and limited suppressive activity via extracellular adenosine. PEG-ADA-treated mice developed multiple autoantibodies and hypothyroidism in contrast to mice treated with bone marrow transplantation or gene therapy. Tregs isolated from PEG-ADA-treated mice lacked suppressive activity, suggesting that this treatment interferes with Treg functionality. The alterations in the CD39/CD73 adenosinergic machinery and loss of function in ADA-deficient Tregs provide new insights into a predisposition to autoimmunity and the underlying mechanisms causing defective peripheral tolerance in ADA-SCID. Trials were registered at www.clinicaltrials.gov as NCT00598481/NCT00599781.

Original languageEnglish
Pages (from-to)1428-1439
Number of pages12
JournalBlood
Volume119
Issue number6
DOIs
Publication statusPublished - Feb 9 2012

Fingerprint

Adenosine Deaminase
Regulatory T-Lymphocytes
Autoimmunity
Metabolism
Adenosine
Machinery
Polyethylene glycols
Genetic Therapy
Gene therapy
Peripheral Tolerance
Enzyme Replacement Therapy
Hypothyroidism
Bone Marrow Transplantation
Autoantibodies
T-cells
Immune System
Immune system
Anti-Inflammatory Agents
Cell membranes
Metabolites

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. / Sauer, Aisha V.; Brigida, Immacolata; Carriglio, Nicola; Hernandez, Raisa Jofra; Scaramuzza, Samantha; Clavenna, Daniela; Sanvito, Francesca; Poliani, Pietro L.; Gagliani, Nicola; Carlucci, Filippo; Tabucchi, Antonella; Roncarolo, Maria Grazia; Traggiai, Elisabetta; Villa, Anna; Aiuti, Alessandro.

In: Blood, Vol. 119, No. 6, 09.02.2012, p. 1428-1439.

Research output: Contribution to journalArticle

Sauer, AV, Brigida, I, Carriglio, N, Hernandez, RJ, Scaramuzza, S, Clavenna, D, Sanvito, F, Poliani, PL, Gagliani, N, Carlucci, F, Tabucchi, A, Roncarolo, MG, Traggiai, E, Villa, A & Aiuti, A 2012, 'Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID', Blood, vol. 119, no. 6, pp. 1428-1439. https://doi.org/10.1182/blood-2011-07-366781
Sauer, Aisha V. ; Brigida, Immacolata ; Carriglio, Nicola ; Hernandez, Raisa Jofra ; Scaramuzza, Samantha ; Clavenna, Daniela ; Sanvito, Francesca ; Poliani, Pietro L. ; Gagliani, Nicola ; Carlucci, Filippo ; Tabucchi, Antonella ; Roncarolo, Maria Grazia ; Traggiai, Elisabetta ; Villa, Anna ; Aiuti, Alessandro. / Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. In: Blood. 2012 ; Vol. 119, No. 6. pp. 1428-1439.
@article{1011344b3e804d2aafa1149b5aa342e5,
title = "Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID",
abstract = "Adenosine acts as anti-inflammatory mediator on the immune system and has been described in regulatory T cell (Treg)-mediated suppression. In the absence of adenosine deaminase (ADA), adenosine and other purine metabolites accumulate, leading to severe immunodeficiency with recurrent infections (ADA-SCID). Particularly ADA-deficient patients with lateonset forms and after enzyme replacement therapy (PEG-ADA) are known to manifest immune dysregulation. Herein we provide evidence that alterations in the purine metabolism interfere with Treg function, thereby contributing to autoimmune manifestations in ADA deficiency. Tregs isolated from PEG-ADA-treated patients are reduced in number and show decreased suppressive activity, whereas they are corrected after gene therapy. Untreated murine ADA -/- Tregs show alterations in the plasma membrane CD39/CD73 ectonucleotidase machinery and limited suppressive activity via extracellular adenosine. PEG-ADA-treated mice developed multiple autoantibodies and hypothyroidism in contrast to mice treated with bone marrow transplantation or gene therapy. Tregs isolated from PEG-ADA-treated mice lacked suppressive activity, suggesting that this treatment interferes with Treg functionality. The alterations in the CD39/CD73 adenosinergic machinery and loss of function in ADA-deficient Tregs provide new insights into a predisposition to autoimmunity and the underlying mechanisms causing defective peripheral tolerance in ADA-SCID. Trials were registered at www.clinicaltrials.gov as NCT00598481/NCT00599781.",
author = "Sauer, {Aisha V.} and Immacolata Brigida and Nicola Carriglio and Hernandez, {Raisa Jofra} and Samantha Scaramuzza and Daniela Clavenna and Francesca Sanvito and Poliani, {Pietro L.} and Nicola Gagliani and Filippo Carlucci and Antonella Tabucchi and Roncarolo, {Maria Grazia} and Elisabetta Traggiai and Anna Villa and Alessandro Aiuti",
year = "2012",
month = "2",
day = "9",
doi = "10.1182/blood-2011-07-366781",
language = "English",
volume = "119",
pages = "1428--1439",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID

AU - Sauer, Aisha V.

AU - Brigida, Immacolata

AU - Carriglio, Nicola

AU - Hernandez, Raisa Jofra

AU - Scaramuzza, Samantha

AU - Clavenna, Daniela

AU - Sanvito, Francesca

AU - Poliani, Pietro L.

AU - Gagliani, Nicola

AU - Carlucci, Filippo

AU - Tabucchi, Antonella

AU - Roncarolo, Maria Grazia

AU - Traggiai, Elisabetta

AU - Villa, Anna

AU - Aiuti, Alessandro

PY - 2012/2/9

Y1 - 2012/2/9

N2 - Adenosine acts as anti-inflammatory mediator on the immune system and has been described in regulatory T cell (Treg)-mediated suppression. In the absence of adenosine deaminase (ADA), adenosine and other purine metabolites accumulate, leading to severe immunodeficiency with recurrent infections (ADA-SCID). Particularly ADA-deficient patients with lateonset forms and after enzyme replacement therapy (PEG-ADA) are known to manifest immune dysregulation. Herein we provide evidence that alterations in the purine metabolism interfere with Treg function, thereby contributing to autoimmune manifestations in ADA deficiency. Tregs isolated from PEG-ADA-treated patients are reduced in number and show decreased suppressive activity, whereas they are corrected after gene therapy. Untreated murine ADA -/- Tregs show alterations in the plasma membrane CD39/CD73 ectonucleotidase machinery and limited suppressive activity via extracellular adenosine. PEG-ADA-treated mice developed multiple autoantibodies and hypothyroidism in contrast to mice treated with bone marrow transplantation or gene therapy. Tregs isolated from PEG-ADA-treated mice lacked suppressive activity, suggesting that this treatment interferes with Treg functionality. The alterations in the CD39/CD73 adenosinergic machinery and loss of function in ADA-deficient Tregs provide new insights into a predisposition to autoimmunity and the underlying mechanisms causing defective peripheral tolerance in ADA-SCID. Trials were registered at www.clinicaltrials.gov as NCT00598481/NCT00599781.

AB - Adenosine acts as anti-inflammatory mediator on the immune system and has been described in regulatory T cell (Treg)-mediated suppression. In the absence of adenosine deaminase (ADA), adenosine and other purine metabolites accumulate, leading to severe immunodeficiency with recurrent infections (ADA-SCID). Particularly ADA-deficient patients with lateonset forms and after enzyme replacement therapy (PEG-ADA) are known to manifest immune dysregulation. Herein we provide evidence that alterations in the purine metabolism interfere with Treg function, thereby contributing to autoimmune manifestations in ADA deficiency. Tregs isolated from PEG-ADA-treated patients are reduced in number and show decreased suppressive activity, whereas they are corrected after gene therapy. Untreated murine ADA -/- Tregs show alterations in the plasma membrane CD39/CD73 ectonucleotidase machinery and limited suppressive activity via extracellular adenosine. PEG-ADA-treated mice developed multiple autoantibodies and hypothyroidism in contrast to mice treated with bone marrow transplantation or gene therapy. Tregs isolated from PEG-ADA-treated mice lacked suppressive activity, suggesting that this treatment interferes with Treg functionality. The alterations in the CD39/CD73 adenosinergic machinery and loss of function in ADA-deficient Tregs provide new insights into a predisposition to autoimmunity and the underlying mechanisms causing defective peripheral tolerance in ADA-SCID. Trials were registered at www.clinicaltrials.gov as NCT00598481/NCT00599781.

UR - http://www.scopus.com/inward/record.url?scp=84856838658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856838658&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-07-366781

DO - 10.1182/blood-2011-07-366781

M3 - Article

VL - 119

SP - 1428

EP - 1439

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -